Imunon, Inc. 8K

IMUNON, Inc. reported Q2 2026 financial results, detailed significant clinical progress for its lead ovarian cancer candidate IMNN-001, announced a $10 million financing, and provided guidance on upcoming corporate and R&D events.

On August 11, 2026, IMUNON, Inc. reported its financial results for the second quarter and first half of 2026 and provided a business update highlighting continued clinical progress for its lead DNA-based immunotherapy candidate IMNN-001 in advanced ovarian cancer, including strong final Phase 2 OVATION 2 overall survival data, a positive Data Monitoring Committee recommendation to continue the pivotal Phase 3 OVATION 3 trial, encouraging preliminary results from an ongoing Phase 2 minimal residual disease study, and faster-than-expected enrollment in OVATION 3. The company also disclosed a June 4, 2026 financing transaction providing $10 million in gross proceeds through the issuance of non-redeemable, non-convertible preferred stock and two secured promissory notes, and summarized its operating performance, showing a modestly higher net loss year-over-year primarily driven by increased research and development expenses associated with OVATION 3, partially offset by lower general and administrative expenses, with $6.9 million in cash and cash equivalents as of June 30, 2026. IMUNON further announced plans to host a research and development day on September 23, 2026 and held a same-day conference call and webcast to discuss these results and developments with investors.

Filing Facts

CIK

749647

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-036985

Alert Tier

6